Core Viewpoint - The stock of Bolekang Vision Cloud-B (02592) has surged over 10% today, with a cumulative increase of nearly 70% this week, driven by positive news regarding patent approvals for its core product CBT-009 [1] Group 1: Stock Performance - As of the latest update, the stock price is at 7.9 HKD, with a trading volume of 6.2189 million HKD [1] - The stock has shown significant growth, with a weekly increase close to 70% [1] Group 2: Patent Approval and Product Development - Bolekang Vision Cloud announced that its wholly-owned subsidiary, ADS USA, has successfully obtained patents from both the Japan Patent Office and the European Patent Office for CBT-009 [1] - CBT-009 is a new atropine eye formulation aimed at treating myopia in children and adolescents aged 5 to 19 [1] - The company anticipates establishing licensing arrangements with major pharmaceutical companies for the production, development, and distribution of CBT-009 in Japan and Europe [1] Group 3: Market Dynamics and Investor Sentiment - The upcoming expiration of lock-up shares for two cornerstone investors on January 3, 2026, is noted, which may impact stock performance [1] - The stock's recent performance suggests a lack of institutional funding, leading to insufficient domestic allocation [1] - Initial trading and dark pool performance were below expectations, potentially due to over-commitment by anchor participants, resulting in a sell-off [1]
拨康视云-B再涨超10% 核心产品CBT-009获得日本及欧洲专利